Immune Checkpoint Blockade

GPTKB entity

Predicate	Object
gptkbp:instanceOf	immunotherapy Cancer Immunotherapy
gptkbp:alternativeName	Checkpoint inhibitor therapy
gptkbp:approvedBy	gptkb:Head_and_neck_cancer gptkb:Melanoma gptkb:Renal_cell_carcinoma gptkb:Bladder_cancer gptkb:Gastric_cancer gptkb:Non-small_cell_lung_cancer Hodgkin lymphoma Hepatocellular carcinoma Triple-negative breast cancer
gptkbp:combines	Chemotherapy Radiotherapy Targeted therapy Other immunotherapies
gptkbp:contraindication	autoimmune disease
gptkbp:discoveredBy	gptkb:James_P._Allison gptkb:Tasuku_Honjo
gptkbp:hasApprovedDrug	gptkb:Ipilimumab gptkb:Nivolumab gptkb:Pembrolizumab
gptkbp:hasBiomarker	gptkb:PD-L1_expression Microsatellite instability Tumor mutational burden
https://www.w3.org/2000/01/rdf-schema#label	Immune Checkpoint Blockade
gptkbp:mechanismOfAction	Blocks immune checkpoint proteins Enhances T cell response
gptkbp:nobelPrizeCategory	Physiology or Medicine
gptkbp:NobelPrizeYear	2018
gptkbp:regulates	T cell activation Antitumor immunity Immune checkpoints
gptkbp:relatedTo	T cell exhaustion Adaptive immunity Immune evasion Tumor microenvironment
gptkbp:routeOfAdministration	Intravenous
gptkbp:sideEffect	Dermatitis Colitis Endocrinopathies Immune-related adverse events Pneumonitis
gptkbp:target	gptkb:CTLA-4 gptkb:PD-1 PD-L1
gptkbp:usedFor	Cancer Treatment
gptkbp:bfsParent	gptkb:ICB
gptkbp:bfsLayer	7